EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia

Yan Chen, Xia Tong, Rongyuan Lu, Zhengfu Zhang, Tao Ma

Frontiers in Pharmacology · 04.07.2024 · 15

DOI: 10.3389/fphar.2024.1404092 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.07.2024. Verfasst von Yan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

All-trans retinoic acid (ATRA) plays a role in tissue development, neural function, reproduction, vision, cell growth and differentiation, tumor immunity, and apoptosis. ATRA can act by inducing autophagic signaling, angiogenesis, cell differentiation, apoptosis, and immune function. In the blood system ATRA was first used with great success in acute promyelocytic leukemia (APL), where ATRA differentiated leukemia cells into mature granulocytes. ATRA can play a role not only in APL, but may also play a role in other hematologic diseases such as immune thrombocytopenia (ITP), myelodysplastic syndromes (MDS), non-APL acute myeloid leukemia (AML), aplastic anemia (AA), multiple myeloma (MM), etc., especially by regulating mesenchymal stem cells and regulatory T cells for the treatment of ITP. ATRA can also increase the expression of CD38 expressed by tumor cells, thus improving the efficacy of daratumumab and CD38-CART. In this review, we focus on the mechanism of action of ATRA, its role in various hematologic diseases, drug combinations, and ongoing clinical trials.

Schlagwörter

Stichwörter der Autor:innen

CD38acute promyelocytic leukemiaall-trans retinoic acidclinical trialsdifferentiationimmune thrombocytopenia

Autor:innen und Institutionen

  • Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • Department of Hematology, Yanyuan People's Hospital, Liangshan, China.

Zitieren

APA

Chen, Y., Tong, X., Lu, R., Zhang, Z., & Ma, T. (2024). All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1404092

Vancouver

Chen Y, Tong X, Lu R, Zhang Z, Ma T. All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1404092

BibTeX
@article{Chen2024,
  author = {Chen, Yan and Tong, Xia and Lu, Rongyuan and Zhang, Zhengfu and Ma, Tao},
  title = {All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1404092}
}
Kostenlos starten →